Management of Metastatic Hormone-Sensitive Prostate Cancer: Is Docetaxel Needed?

J Clin Oncol. 2022 Nov 1;40(31):3573-3575. doi: 10.1200/JCO.22.00705. Epub 2022 Jun 20.

Authors

Adi Kartolo¹, Ian F Tannock², Francisco E Vera Badillo¹

Affiliations

¹ Department of Oncology, Cancer Centre of Southeastern Ontario, Queen's University, Kingston, Ontario, Canada.
² Department of Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.

PMID: 35724342
DOI: 10.1200/JCO.22.00705

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Androgen Antagonists / therapeutic use
Antineoplastic Combined Chemotherapy Protocols
Docetaxel / therapeutic use
Hormones / therapeutic use
Humans
Male
Prostatic Neoplasms* / drug therapy
Prostatic Neoplasms* / pathology

Substances

Docetaxel
Androgen Antagonists
Hormones